Efficacy of Sofosbuvir and Daclatasvir in Achieving the End Treatment Response and Sustained Viral Response in Patients infected with Hepatitis C Virus Genotype 3
نویسندگان
چکیده
Objective: To ascertain the efficacy of sofosbuvir combined with daclatasvir against hepatitis C genotype 3 infection.
 Study Design: Prospective longitudinal study.
 Place and Duration Study: Ayub Teaching Hospital, Abbottabad, Pakistan, from Nov 2018 to Jan 2020.
 Methodology: About 262 patients were treated during study. Patients symptoms associated liver failure, including ascites, uncontrolled bleeding, encephalopathy other comorbidities, excluded diagnosed infection given follow-up visits at 12 24 weeks treatment. Primary outcome variables end treatment response, sustained viral nonresponders, relapse rate. In addition, secondary outcomes patient age, gender, baseline load observed.
 Results: The mean age was 39.8 ± 8.2 years. twelve-week course Sofosbuvir Daclatasvir produced an response (ETR) 98.9%, while virological 95.8%. combination had no adverse effects, none reported discontinuation. There deaths due treatment.
 Conclusion: current study indicates that using in conjunction is effective drug regime Hepatitis virus, type infection.
منابع مشابه
Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus
BACKGROUND As treatments for chronic hepatitis C are moving away from interferon-containing regimens, the most appropriate allocation of resources to higher cost, interferon-free, direct-acting antiviral (DAA) regimens needs to be assessed. Hepatitis C virus (HCV) genotype 3 is associated with faster disease progression and has fewer treatment options, historically, than other HCV genotypes. Th...
متن کاملEarly viral kinetics and response to treatment in a hepatitis C virus genotype 5 infected patient
Genotype 5 hepatitis C has been poorly studied despite its worldwide spread. We have analyzed the early kinetics of genotype 5 hepatitis C virus RNA during pegylated interferon/ribavirin treatment in a 59-year-old man with active liver necroinflammatory changes and advanced liver fibrosis. The patient had a high viral load but a small serum level of hepatitis C core antigen. On combination anti...
متن کاملPredictors of sustained virological response in patients with hepatitis C virus genotype 3 infection
AIM OF THE STUDY To assess predictors of sustained virological response (SVR) in patients with chronic hepatitis C virus (HCV) genotype 3 treated with standard therapy. MATERIAL AND METHODS We retrospectively investigated data of 116 consecutive treatment-naïve patients chronically infected with HCV genotype 3, treated with pegylated interferon alpha (PegIFNα) and ribavirin (RBV) for 24 weeks...
متن کاملOutcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection
Background and aims Treatment of hepatitis C virus (HCV) changed dramatically with the introduction of oral direct-acting antiviral drugs due to their high antiviral potency and safety profile. Sofosbuvir plus daclatasvir combination therapy was extensively investigated in HCV genotypes 1, 2, and 3, while published data regarding its real-life application in the treatment of genotype 4 is lacki...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Pakistan Armed Forces Medical Journal
سال: 2022
ISSN: ['2411-8842', '0030-9648']
DOI: https://doi.org/10.51253/pafmj.v72i3.4470